BioLife Solutions, Inc.
BLFS
$23.95
-$0.79-3.19%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | 35.12% | 34.37% | 69.75% | 51.08% | 20.22% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 35.12% | 34.37% | 69.75% | 51.08% | 20.22% |
| Cost of Revenue | 49.87% | 45.15% | 512.74% | 204.99% | 22.46% |
| Gross Profit | 27.94% | 29.09% | 23.66% | 20.50% | 19.16% |
| SG&A Expenses | 12.55% | 12.97% | 32.31% | 15.17% | -1.80% |
| Depreciation & Amortization | 533.98% | 485.17% | -122.10% | -116.15% | -112.86% |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 33.86% | 29.03% | 64.40% | 28.80% | -7.17% |
| Operating Income | 24.81% | 60.02% | 52.31% | 86.11% | 92.00% |
| Income Before Tax | -120.80% | -44.95% | -788.31% | -18.69% | 58.88% |
| Income Tax Expenses | 336.59% | 228.95% | 183.39% | 184.00% | 58.59% |
| Earnings from Continuing Operations | -124.33% | -46.14% | -712.89% | -20.25% | 58.88% |
| Earnings from Discontinued Operations | 275.84% | 172.30% | 122.61% | 116.21% | 90.12% |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 71.55% | 77.23% | 93.26% | 92.63% | 83.86% |
| EBIT | 24.81% | 60.02% | 52.31% | 86.11% | 92.00% |
| EBITDA | -47.47% | -51.65% | -45.39% | 866.67% | 151.49% |
| EPS Basic | 72.14% | 77.99% | 94.19% | 93.40% | 84.29% |
| Normalized Basic EPS | 343.68% | 152.45% | 144.38% | 99.17% | 93.70% |
| EPS Diluted | 66.96% | 76.16% | 93.12% | 92.91% | 83.73% |
| Normalized Diluted EPS | 335.75% | 151.22% | 142.94% | 98.97% | 93.60% |
| Average Basic Shares Outstanding | 3.42% | 3.66% | 3.88% | 4.41% | 4.91% |
| Average Diluted Shares Outstanding | 3.29% | 4.45% | 5.75% | 5.86% | 6.38% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |